Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine implant - Innocoll

Drug Profile

Bupivacaine implant - Innocoll

Alternative Names: B-Implant; Bupivacaine HCl collagen-matrix implant - Innocoll; Bupivacaine-collagen bioresorbable implant - Innocoll; CollaRx® Bupivacaine implant; INL-001; INN-LD-01; XaraColl

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innocoll
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain
  • No development reported Pain

Most Recent Events

  • 13 Mar 2019 Bupivacaine implant is still in preregistration for Postoperative pain in USA
  • 15 Aug 2017 Innocoll completes a phase II trial for Postoperative pain in USA (NCT03234374)
  • 24 Jul 2017 Innocoll has been acquired by Gurnet point capital
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top